Citius Oncology (CTOR) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CTOR Citius Oncology

Watchlist

1.250
-0.030-2.34%

Close Feb 14 16:00 ET

1.240
-0.010-0.80%

Post 19:58 ET

89.44MMarket Cap-4.22P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Citius Oncology 1Q Rev $0.00 >CTOR
Dow JonesFeb 14 16:58 ET
Express News | Citius Oncology Inc: Qtrly Net Loss per Share $0.09
ReutersFeb 14 16:53 ET
8-K: Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
SECFeb 14 16:50 ET · Announcements
10-Q: Quarterly report
SECFeb 14 16:38 ET · Announcements
Express News | Citius Oncology Q1 2025 GAAP EPS $(1.30) Misses $(0.06) Estimate
BenzingaFeb 14 16:33 ET
Press Release: Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Dow JonesFeb 14 16:30 ET

Comments

Teddy123

Feb 14 19:00

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

$Citius Oncology (CTOR.US)$
Citius Oncology Preps LYMPHIR Cancer Drug Launch While Strategic Review Unfolds

Trytosaveabit

Feb 6 07:58

News

$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$ Reuters· just
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services

Trytosaveabit

Jan 7 07:12

News

Jaguar8

Jan 7 07:08

NEWS

$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...